Juno Therapeutics Appoints Jeffrey Bluestone As Scientific Advisor

SEATTLE, Dec. 1, 2014 /PRNewswire/ -- Juno Therapeutics today announced the appointment of Jeffrey Bluestone, PhD, as scientific advisor. He will advise the company on T cell therapies, including potential applications in autoimmune disease and organ transplantation.

Juno Therapeutics.
"We are delighted to have the opportunity to work with Dr. Bluestone, one of the world's outstanding T cell biologists, who has made major contributions in basic immunology and in the translation of those discoveries to clinical trials," said Juno CEO Hans Bishop.

Bluestone's scientific work includes building a broad understanding of human immune responses at the molecular level, with significant contributions to stem cell research and immunology. He has published more than 400 peer-reviewed publications in journals including Nature, Nature Immunology, the Journal of Immunology, and Diabetes.

"I am excited to be working with Juno's outstanding scientific founders and team to translate discoveries in immune tolerance into medical applications," said Bluestone.

Bluestone is the A.W. and Mary Margaret Clausen Distinguished Professor and Director of the Hormone Research Institute at the University of California San Francisco, where he guides the institute's autoimmunity research and clinical initiatives in immune tolerance and T cell therapies. He has held appointments at the University of Chicago and the National Cancer Institute, and is a member of the American Academy of Arts and Sciences and the Institute of Medicine. After earning his BS in biology and MS in microbiology from Rutgers University, Bluestone earned a PhD in immunology from the Cornell Graduate School of Medical Science.

About Juno

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors.  Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. The company's long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.  Juno brings together innovative technologies from three of the world's leading research institutions the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children's Research Institute. 


Logo - http://photos.prnewswire.com/prnh/20140113/DC45426LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/juno-appoints-jeffrey-bluestone-as-scientific-advisor-300002281.html

SOURCE Juno Therapeutics

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.